社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
仓都嘉满
不踏空不满仓
IP属地：云南
+关注
帖子 · 71
帖子 · 71
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
仓都嘉满
仓都嘉满
·
09-07
$凯乐士科技(02729)$
凯乐士正式进入港股通，这意味着内地投资者自此可通过沪深港通直接买卖凯乐士科技，正式解锁南向资金
看
392
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
09-07
$宝济药业-B(02659)$
宝济目前的势头还是比较平稳，希望后面是横有多长竖就有多高
看
460
回复
评论
点赞
1
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
09-07
$海致科技集团(02706)$
国盛证券在研报中表示，海致更适合承担高可靠、强逻辑、重交付的产业AI场景，有望成为主权AI和企业智能体落地的重要标的
看
293
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-28
$海致科技集团(02706)$
招银继续给了买入评级，希望能顺利实现招银给的买入目标价，冲起来
看
745
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-10
$中慧生物-B(02627)$
中慧现在是继续停牌，不过近期的创新药板块貌似有轮动的迹象，这点值得关注
看
763
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-10
$同源康医药-B(02410)$
同源康自主研发的TY-9591高选择性不可逆EGFR肺癌靶向药，是国产非小细胞肺癌赛道高潜力创新管线，具备差异化临床优势与广阔市场空间
看
548
回复
评论
点赞
1
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-10
$海致科技集团(02706)$
在人工智能(AI)赛道呈现高低切换的市场背景下，公募基金的持仓与资金意愿正向股价低位的AI应用领域扩散
看
825
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-04
$同源康医药-B(02410)$
同源康的TY-302、TY-2136b等多款产品稳步推进临床，覆盖不同靶点、不同耐药机制的肿瘤治疗场景，持续丰富产品矩阵，规避单一品种风险，为公司中长期发展储备充足管线动能
看
925
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-04
$海致科技集团(02706)$
海致已经是今时不同往日了，哪怕是大盘表现不佳，海致也有机会强势上涨回来
看
588
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
仓都嘉满
仓都嘉满
·
08-04
$中慧生物-B(02627)$
随着产品矩阵的日趋多元，中慧生物的收入结构将更加稳健，抵御单一品种市场波动的能力也将显著增强
看
808
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4229664385867060","uuid":"4229664385867060","gmtCreate":1766561166009,"gmtModify":1766564408161,"name":"仓都嘉满","pinyin":"cdjmcangdoujiaman","introduction":"","introductionEn":null,"signature":"不踏空不满仓","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":71,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"云南","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":605026929148200,"gmtCreate":1788748708720,"gmtModify":1788748711046,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02729\">$凯乐士科技(02729)$ </a> 凯乐士正式进入港股通，这意味着内地投资者自此可通过沪深港通直接买卖凯乐士科技，正式解锁南向资金","listText":"<a href=\"https://laohu8.com/S/02729\">$凯乐士科技(02729)$ </a> 凯乐士正式进入港股通，这意味着内地投资者自此可通过沪深港通直接买卖凯乐士科技，正式解锁南向资金","text":"$凯乐士科技(02729)$ 凯乐士正式进入港股通，这意味着内地投资者自此可通过沪深港通直接买卖凯乐士科技，正式解锁南向资金","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605026929148200","isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605025391342992,"gmtCreate":1788748334670,"gmtModify":1788748336714,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 宝济目前的势头还是比较平稳，希望后面是横有多长竖就有多高","listText":"<a href=\"https://laohu8.com/S/02659\">$宝济药业-B(02659)$ </a> 宝济目前的势头还是比较平稳，希望后面是横有多长竖就有多高","text":"$宝济药业-B(02659)$ 宝济目前的势头还是比较平稳，希望后面是横有多长竖就有多高","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605025391342992","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605025193657592,"gmtCreate":1788748267393,"gmtModify":1788748269642,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 国盛证券在研报中表示，海致更适合承担高可靠、强逻辑、重交付的产业AI场景，有望成为主权AI和企业智能体落地的重要标的","listText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 国盛证券在研报中表示，海致更适合承担高可靠、强逻辑、重交付的产业AI场景，有望成为主权AI和企业智能体落地的重要标的","text":"$海致科技集团(02706)$ 国盛证券在研报中表示，海致更适合承担高可靠、强逻辑、重交付的产业AI场景，有望成为主权AI和企业智能体落地的重要标的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605025193657592","isVote":1,"tweetType":1,"viewCount":293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601527306670928,"gmtCreate":1787894214474,"gmtModify":1787894216763,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 招银继续给了买入评级，希望能顺利实现招银给的买入目标价，冲起来","listText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 招银继续给了买入评级，希望能顺利实现招银给的买入目标价，冲起来","text":"$海致科技集团(02706)$ 招银继续给了买入评级，希望能顺利实现招银给的买入目标价，冲起来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601527306670928","isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":595191483814392,"gmtCreate":1786328547178,"gmtModify":1786328548958,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 中慧现在是继续停牌，不过近期的创新药板块貌似有轮动的迹象，这点值得关注","listText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 中慧现在是继续停牌，不过近期的创新药板块貌似有轮动的迹象，这点值得关注","text":"$中慧生物-B(02627)$ 中慧现在是继续停牌，不过近期的创新药板块貌似有轮动的迹象，这点值得关注","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/595191483814392","isVote":1,"tweetType":1,"viewCount":763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":595190810170384,"gmtCreate":1786328420006,"gmtModify":1786328422143,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康自主研发的TY-9591高选择性不可逆EGFR肺癌靶向药，是国产非小细胞肺癌赛道高潜力创新管线，具备差异化临床优势与广阔市场空间","listText":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康自主研发的TY-9591高选择性不可逆EGFR肺癌靶向药，是国产非小细胞肺癌赛道高潜力创新管线，具备差异化临床优势与广阔市场空间","text":"$同源康医药-B(02410)$ 同源康自主研发的TY-9591高选择性不可逆EGFR肺癌靶向药，是国产非小细胞肺癌赛道高潜力创新管线，具备差异化临床优势与广阔市场空间","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/595190810170384","isVote":1,"tweetType":1,"viewCount":548,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":595190604784656,"gmtCreate":1786328369863,"gmtModify":1786328371872,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 在人工智能(AI)赛道呈现高低切换的市场背景下，公募基金的持仓与资金意愿正向股价低位的AI应用领域扩散","listText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 在人工智能(AI)赛道呈现高低切换的市场背景下，公募基金的持仓与资金意愿正向股价低位的AI应用领域扩散","text":"$海致科技集团(02706)$ 在人工智能(AI)赛道呈现高低切换的市场背景下，公募基金的持仓与资金意愿正向股价低位的AI应用领域扩散","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/595190604784656","isVote":1,"tweetType":1,"viewCount":825,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":593034919592616,"gmtCreate":1785811500340,"gmtModify":1785811502515,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康的TY-302、TY-2136b等多款产品稳步推进临床，覆盖不同靶点、不同耐药机制的肿瘤治疗场景，持续丰富产品矩阵，规避单一品种风险，为公司中长期发展储备充足管线动能","listText":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康的TY-302、TY-2136b等多款产品稳步推进临床，覆盖不同靶点、不同耐药机制的肿瘤治疗场景，持续丰富产品矩阵，规避单一品种风险，为公司中长期发展储备充足管线动能","text":"$同源康医药-B(02410)$ 同源康的TY-302、TY-2136b等多款产品稳步推进临床，覆盖不同靶点、不同耐药机制的肿瘤治疗场景，持续丰富产品矩阵，规避单一品种风险，为公司中长期发展储备充足管线动能","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/593034919592616","isVote":1,"tweetType":1,"viewCount":925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":593034784309744,"gmtCreate":1785811460406,"gmtModify":1785811462253,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 海致已经是今时不同往日了，哪怕是大盘表现不佳，海致也有机会强势上涨回来","listText":"<a href=\"https://laohu8.com/S/02706\">$海致科技集团(02706)$ </a> 海致已经是今时不同往日了，哪怕是大盘表现不佳，海致也有机会强势上涨回来","text":"$海致科技集团(02706)$ 海致已经是今时不同往日了，哪怕是大盘表现不佳，海致也有机会强势上涨回来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/593034784309744","isVote":1,"tweetType":1,"viewCount":588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":593033497945336,"gmtCreate":1785811208306,"gmtModify":1785811210669,"author":{"id":"4229664385867060","authorId":"4229664385867060","name":"仓都嘉满","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4229664385867060","authorIdStr":"4229664385867060"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 随着产品矩阵的日趋多元，中慧生物的收入结构将更加稳健，抵御单一品种市场波动的能力也将显著增强","listText":"<a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 随着产品矩阵的日趋多元，中慧生物的收入结构将更加稳健，抵御单一品种市场波动的能力也将显著增强","text":"$中慧生物-B(02627)$ 随着产品矩阵的日趋多元，中慧生物的收入结构将更加稳健，抵御单一品种市场波动的能力也将显著增强","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/593033497945336","isVote":1,"tweetType":1,"viewCount":808,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}
